2,298
Views
2
CrossRef citations to date
0
Altmetric
Case Reports

A case of an 11-year-old girl diagnosed with OCD developing giggle incontinence following addition of aripiprazole to treatment

ORCID Icon, ORCID Icon & ORCID Icon
Pages 343-345 | Received 17 Nov 2017, Accepted 01 Dec 2017, Published online: 12 Dec 2017

References

  • Nevéus T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardization Committee of the International Children’s Continence Society. J Urol. 2006;176:314–324. doi: 10.1016/S0022-5347(06)00305-3
  • Berry AK, Zderic S, Carr M. Methylphenidate for giggle incontinence. J Urol. 2009;182:2028–2032. doi: 10.1016/j.juro.2009.04.085
  • Storch EA, Merlo LJ. Obsessive-compulsive disorder: strategies for using CBT and pharmacotherapy. J Fam Practice. 2006;55:329–333.
  • Vloet TD, Simons M, Herpertz-Dahlmann B. Psychotherapeutic and pharmacological treatment of pediatric obsessive-compulsive disorder. Z Kinder Jugendpsychiatr Psychother. 2012;40:29–39. doi: 10.1024/1422-4917/a000147
  • Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–389. doi: 10.1124/jpet.102.033175
  • Ulay HT. Aripiprazole for obsessive compulsive disorder in children and adolescents: case reports. Turk J Child Adolesc Ment Health. 2010;17:91–96.
  • Kose S, Akin E, Cetin M. Adverse drug reactions and causality: the Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Psychiatry Clin Psychopharmacol. 2017;27:205–206. doi: 10.1080/24750573.2017.1332512
  • Chang JH, Lee KY, Kim TB, et al. Clinical and urodynamic effect of methylphenidate for the treatment of giggle incontinence (Enuresis Risoria). Neurourol Urodyn. 2011;30:58–61. doi: 10.1002/nau.20901
  • Overeem S, Lammers GJ, van Dijk JG. Weak with laughter. Lancet. 1999;354:838. doi: 10.1016/S0140-6736(99)80023-3
  • Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Review article. Sleep Med Rev. 2000;4:57–99. doi: 10.1053/smrv.1999.0069
  • Mignot E, Guilleminault C, Bowersox S, et al. Effect of alpha 1-adrenoceptors blockade with prazosin in canine narcolepsy. Brain Res. 1988;444:184–188. doi: 10.1016/0006-8993(88)90927-4
  • Nishino S, Arrigoni J, Valtier D, et al. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci. 1991;11:2666–2671. doi: 10.1523/JNEUROSCI.11-09-02666.1991
  • Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother. 2002;3:1773–1781. doi: 10.1517/14656566.3.12.1773
  • Hall DA, Agarwal P, Griffith A, et al. Movement disorders associated with aripiprazole use: a case series. Int J Neurosci. 2009;119:2274–2279. doi: 10.3109/00207450903225553
  • Toğul H, Budaklı AA, Algül A, et al. Aripiprazole induced priapism. Bull Clin Psychopharmacol. 2012;22(Suppl. 1):S149.